Medical Molecular Morphology

, Volume 46, Issue 4, pp 185–192

Clinical significance of cell cycle inhibitors in hepatocellular carcinoma

Authors

    • Department of Medical TechnologyNiigata University Graduate School of Health Sciences
  • Toshifumi Wakai
    • Division of Digestive and General SurgeryNiigata University Graduate School of Medical and Dental Sciences
  • Masayuki Kubota
    • Division of Pediatric SurgeryNiigata University Graduate School of Medical and Dental Sciences
  • Masaaki Takamura
    • Division of Gastroenterology and HepatologyNiigata University Graduate School of Medical and Dental Sciences
  • Satoshi Yamagiwa
    • Division of Gastroenterology and HepatologyNiigata University Graduate School of Medical and Dental Sciences
  • Yutaka Aoyagi
    • Division of Gastroenterology and HepatologyNiigata University Graduate School of Medical and Dental Sciences
  • Mami Osawa
    • Division of Pediatric SurgeryNiigata University Graduate School of Medical and Dental Sciences
  • Shun Fujimaki
    • Department of Medical TechnologyNiigata University Graduate School of Health Sciences
  • Ayumi Sanpei
    • Department of Medical TechnologyNiigata University Graduate School of Health Sciences
  • Takuya Genda
    • Department of Gastroenterology and HepatologyJuntendo University Shizuoka Hospital
  • Takafumi Ichida
    • Department of Gastroenterology and HepatologyJuntendo University Shizuoka Hospital
Award Review

DOI: 10.1007/s00795-013-0047-7

Cite this article as:
Matsuda, Y., Wakai, T., Kubota, M. et al. Med Mol Morphol (2013) 46: 185. doi:10.1007/s00795-013-0047-7

Abstract

It is well accepted that cell cycle regulators are strongly implicated in the progression of cancer development. p16 and p27 are potent cyclin-dependent kinase (CDK) inhibitors involved in G1 phase progression, and are regarded as adverse prognostic biomarkers for various types of cancers. It has been reported that the main mechanism for p16 inactivation is aberrant DNA methylation, while p27 is exclusively inactivated by proteasome-mediated protein degradation. We have found that p27 is decreased in around half of hepatocellular carcinomas (HCCs), and in some cases p27 is inactivated by inappropriate interaction with cyclin D1/CDK4 complexes. In such cases, p16 is concomitantly inactivated through DNA methylation. Taking into consideration the complex interaction between p16 and p27, a comprehensive analysis including p16 and p27 would be useful for predicting the prognosis of HCC patients.

Keywords

Cell cycle p16 Id-1 p27 Liver cirrhosis Hepatocellular carcinoma

Copyright information

© The Japanese Society for Clinical Molecular Morphology 2013